| 000 | 01072 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250517115824.0 | ||
| 264 | 0 | _c20180103 | |
| 008 | 201801s 0 0 eng d | ||
| 022 | _a1473-6527 | ||
| 024 | 7 |
_a10.1097/QCO.0000000000000319 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aForton, Daniel M | |
| 245 | 0 | 0 |
_aHow much of a problem is resistance in treating hepatitis C? _h[electronic resource] |
| 260 |
_bCurrent opinion in infectious diseases _c12 2016 |
||
| 300 |
_a625-631 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Resistance, Viral |
| 650 | 0 | 4 |
_aHepacivirus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Failure |
| 650 | 0 | 4 | _aViral Nonstructural Proteins |
| 773 | 0 |
_tCurrent opinion in infectious diseases _gvol. 29 _gno. 6 _gp. 625-631 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/QCO.0000000000000319 _zAvailable from publisher's website |
| 999 |
_c26459693 _d26459693 |
||